Announcement on Japanese Representation Business Agreement between Richmond Pharmacology and ACRONET Corporation.

Posted:
15
November 2010

We are pleased to announce that ACRONET Corporation (Head office: Bunkyo-ku, Tokyo, President & CEO: Mr Hisashi Uematsu, hereafter referred to as ACRONET) and Richmond Pharmacology Ltd (Head office: St George�s University of London, England, UK, Managing Director: Dr. J�rg T�ubel, hereafter referred to as Richmond) recently executed the Japanese representation agreement. Hereafter ACRONET, as the Japanese representative of Richmond, will start to assist Japanese pharmaceutical companies prior to and during the conduct of their early phase clinical studies by Richmond.

The UK has an established reputation as the preferred country for drug development in the EU. This is because the UK has a stable environment supporting drug discovery through all clinical phases due to the proactive promotion of drug development by the government.Also, due to the established regulatory environment, the UK provides an ideal location for conducting clinical studies and efficient new drug applications.

Consequently, the UK has traditionally produced many excellent companies related to pharmaceutical drug development. Richmond Pharmacology, as an excellent CRO in the UK, has to date supported many pharmaceutical companies, including Japanese Pharmaceutical companies.Because of this situation, ACRONET and Richmond executed the representation agreement to support Japanese pharmaceutical companies for there early phase clinical studies.

Hereafter, as a Japanese representative of Richmond, ACRONET will promote co-marketing activities together with Richmond and act as a contact and a liaison point in Japan to assist Japanese Pharmaceutical companies for their successful Phase I and POC studies, aiming for reducing cost and shortening period for drug development. We will commence sales and marketing promotion for RPL services from September 2009 and hope to achieve annual sales ca JPY 200 million in the total amount of signed contracts.

View Press Release

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more